OncoMatch/Clinical Trials/NCT00722228
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Is NCT00722228 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Autologous or Allogeneic tumor cells for colorectal cancer.
Treatment: Autologous or Allogeneic tumor cells — This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Ovarian Cancer
Gastric Cancer
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Renal Cell Carcinoma
Melanoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: cytotoxic chemotherapy
Failure of at least one chemotherapy protocol
Lab requirements
Blood counts
absolute neutrophil count greater than 1000/mm3
Kidney function
serum creatinine less than or equal to 1.6 mg/dl
Liver function
serum alt/ast less than three times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify